Jeffrey Yordon - Athenex COO and President Athenex Pharmaceutical Division
President
Mr. Jeffrey M. Yordon serves as Chief Operating Officer and President, Athenex Pharmaceutical Division of the company. Mr. Yordon joined our company as President, Athenex Pharmaceutical Division in April 2016 and in February 2017 he was appointed as our Chief Operating Officer. Mr. Yordon has held multiple senior management positions in the pharmaceutical industry over the last 46 years. Mr. Yordon was the Founder, Chairman and Chief Executive Officer of Sagent Pharmaceuticals from 2007 until joining us in 2016. Prior to that Mr. Yordon was the COO of American Pharmaceutical Partners where he was a cofounder until the company was eventually sold to Fresenius. Mr. Yordon was the CEO of Faulding Pharmaceuticals, CEO and founder of YorPharm, COO of Gensia Pharmaceuticals and he was involved in the sale of each of these companies to Apotex, Teva and Hospira, respectively. Mr. Yordon was an Ernst Young Entrepreneur of the Year in 2011, was inducted into the Chicago Entrepreneur Hall of Fame in 2014, won a prestigious Innovation Award from the City of Chicago, was appointed to the Chicago Innovation Council in 2014, was appointed by Governor Rauner to the Illinois Sports Facilities Authority in 2015, was appointed to be the Chairman of the Board of the Northern Illinois University Foundation, is the Chair of the NIU Political Science Advisory Panel and is actively involved in the NIU Athletic program since 2017.
| Age | 74 |
| Tenure | 8 years |
| Phone | 716 427-2950 |
| Web | www.athenex.com |
Athenex Management Efficiency
The company has return on total asset (ROA) of (0.1965) % which means that it has lost $0.1965 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.2727) %, meaning that it created substantial loss on money invested by shareholders. Athenex's management efficiency ratios could be used to measure how well Athenex manages its routine affairs as well as how well it operates its assets and liabilities.Athenex currently holds 42.36 M in liabilities with Debt to Equity (D/E) ratio of 4.58, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Athenex has a current ratio of 1.28, suggesting that it is in a questionable position to pay out its financial obligations when due. Note, when we think about Athenex's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | PRESIDENT Age | ||
| Leslie Robbins | CytomX Therapeutics | N/A | |
Management Performance
| Return On Equity | -19.27 | |||
| Return On Asset | -0.2 |
Athenex Leadership Team
Elected by the shareholders, the Athenex's board of directors comprises two types of representatives: Athenex inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Athenex. The board's role is to monitor Athenex's management team and ensure that shareholders' interests are well served. Athenex's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Athenex's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Allen Barnett, CoFounder Emeritus | ||
| Daniel MD, Pres Therapy | ||
| Jeffrey Yordon, COO and President Athenex Pharmaceutical Division | ||
| John Matthei, Chief Officer | ||
| Jacqueline Li, VP Devel | ||
| Caileigh Dougherty, Director Relations | ||
| Joe CFA, Chief Officer | ||
| BS MB, Chief Officer | ||
| FRCP MBBS, Chairman CEO | ||
| Steven Adams, Chief Officer |
Athenex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Athenex a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -19.27 | |||
| Return On Asset | -0.2 | |||
| Profit Margin | (1.01) % | |||
| Operating Margin | (0.72) % | |||
| Current Valuation | 82.22 M | |||
| Shares Outstanding | 8.7 M | |||
| Shares Owned By Insiders | 9.73 % | |||
| Shares Owned By Institutions | 29.87 % | |||
| Number Of Shares Shorted | 356.33 K | |||
| Price To Earning | (4.87) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Athenex Stock
If you are still planning to invest in Athenex check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Athenex's history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |